Last reviewed · How we verify
CKD-828
CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth.
CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | CKD-828 |
|---|---|
| Also known as | Telminuvo |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Dual VEGFR2/FGFR1 tyrosine kinase inhibitor |
| Target | VEGFR2, FGFR1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CKD-828 selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1), two key drivers of tumor angiogenesis and growth. By targeting both pathways simultaneously, the drug aims to overcome resistance mechanisms and provide enhanced anti-tumor activity in solid malignancies. This dual-target approach is designed to be more effective than single-pathway inhibitors in suppressing new blood vessel formation that tumors require for growth and metastasis.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Anorexia
Key clinical trials
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5) (PHASE1)
- A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg (PHASE1)
- A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) (PHASE1)
- Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-828 CI brief — competitive landscape report
- CKD-828 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI